ERBB2 and breast cancer: In this cohort of 73 patients with HR positive and HER-2 negative breast cancer treated with ribociclib, an increase in SAT volume and an increase in SAT SUV mean were found to be independent risk factors for progression in patients with metastatic breast cancer.